# Trial of CF101 to Treat Patients With Psoriasis

> **NCT01265667** · PHASE2,PHASE3 · COMPLETED · sponsor: **Can-Fite BioPharma** · enrollment: 293 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** CF101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01265667
- **Lead sponsor:** Can-Fite BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2015-03
- **Final completion:** 2015-05
- **Target enrollment:** 293 (ACTUAL)
- **Last updated:** 2020-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01265667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01265667, "Trial of CF101 to Treat Patients With Psoriasis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01265667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*